Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment.
OBJECTIVE
The purpose of this health technology assessment (HTA), commissioned by the German Agency for HTA at the German Federal Ministry of Health and Social Security, was to systematically review the evidence on effectiveness and cost-effectiveness of antiviral treatment (AVT) for initial chronic hepatitis C (CHC) and to apply these data in the context of the German health care system.


METHODS
A systematic literature search was conducted to identify randomised controlled trials (RCTs), meta-analyses, and HTAs that evaluated initial AVT for CHC. A modified version of the German Hepatitis C Model (GEHMO)--a decision-analytic Markov model--was used to determine long-term morbidity, life expectancy, quality of life, costs and cost-effectiveness of different treatment strategies. Model parameters were derived from German databases, international RCTs, and a Cochrane Review.


RESULTS
Overall, 9 RCTs, 2 HTA reports, 1 Cochrane review, and 2 meta-analyses examining medical effectiveness of antiviral combination therapy, as well as 7 economic evaluations, met the inclusion criteria. These studies indicate that combination therapy with peginterferon plus ribavirin produced the highest sustained virological response rates (54-61%), followed by interferon plus ribavirin with 38-54%, and interferon monotherapy with 11-21%. Based on international cost-effectiveness studies, interferon plus ribavirin is cost-effective compared to interferon monotherapy. No published articles were available regarding cost-effectiveness of peginterferon plus ribavirin. In our decision analysis, these findings were confirmed and the discounted incremental cost-effectiveness ratio for peginterferon plus ribavirin was euro 9,800 per quality-adjusted life-year gained compared to interferon monotherapy (as the next best non-dominated strategy). Sensitivity analyses showed robust results across a wide range of model parameters.


CONCLUSIONS
This HTA suggests that initial combination therapy prolongs life, improves quality of life, and is cost-effective in patients with CHC. Combination of peginterferon and ribavirin is the most effective and efficient treatment strategy among the examined options.
Siebert
Uwe
U
Program on Health Technology Assessment and Decision Sciences, Bavarian Public Health Research and Coordinating Center, Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Germany. siebert@ibe.med.uni-muenchen.de
Sroczynski
Gaby
G
Ann Intern Med. 2000 Feb 15;132(4):296-305
10681285
Liver. 1993 Oct;13(5):274-8
7505044
J Hepatol. 2000 Oct;33(4):651-8
11059872
J Hepatol. 2001 Mar;34(3):441-6
11322207
Health Technol Assess. 2000;4(33):1-67
11134916
Hepatology. 2002 Nov;36(5 Suppl 1):S47-56
12407576
Lancet. 2001 Sep 22;358(9286):958-65
11583749
J Hepatol. 1990 Jan;10(1):69-76
2106548
Semin Liver Dis. 1999;19 Suppl 1:57-65
10349693
Hepatology. 2001 Oct;34(4 Pt 1):809-16
11584380
N Engl J Med. 1999 Aug 19;341(8):556-62
10451460
Hepatology. 1999 Nov;30(5):1318-24
10534357
Ann Intern Med. 1990 Dec 1;113(11):852-71
2146912
Health Policy. 1996 Sep;37(3):163-83
10160021
Gastroenterology. 1996 Nov;111(5):1307-12
8898645
Gut. 2002 Feb;50(2):253-8
11788569
J Hepatol. 1999 May;30(5):956-61
10365827
Lancet. 1998 Jan 10;351(9096):83-7
9439491
Health Econ. 1998 Sep;7(6):481-93
9809707
Am J Gastroenterol. 2000 Jun;95(6):1524-30
10894590
BMJ. 2001 Nov 17;323(7322):1151-5
11711405
Cochrane Database Syst Rev. 2002;(1):CD002234
11869633
Pharmacoeconomics. 1998;14 Suppl 2:39-56
10344922
Hepatology. 1991 Dec;14(6):969-74
1959884
J Hepatol. 1992 Nov;16(3):273-81
1487603
Eur J Gastroenterol Hepatol. 2001 May;13(5):483-8
11396525
Ann Intern Med. 1999 May 18;130(10):857-8
10366377
Am J Med. 2000 Apr 1;108(5):366-73
10759092
J Viral Hepat. 1999 Jan;6(1):35-47
10847128
N Engl J Med. 1998 Nov 19;339(21):1485-92
9819446
Ann Intern Med. 1993 Jul 15;119(2):110-5
8512159
J Hepatol. 2000 Sep;33(3):448-55
11020001
Lancet. 1998 Oct 31;352(9138):1426-32
9807989
Int J Technol Assess Health Care. 1992 Fall;8(4):671-82
1464487
Scand J Gastroenterol. 2001 Aug;36(8):870-6
11495084
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Semin Liver Dis. 2000;20(1):17-35
10895429
Ann Intern Med. 1997 Nov 15;127(10):855-65
9382363
J Hepatol. 1995;23 Suppl 2:8-12
8720287
Hepatology. 1994 Jun;19(6):1513-20
8188183
Hepatology. 1981 Sep-Oct;1(5):431-5
7308988
J Gastroenterol Hepatol. 2002 Apr;17(4):423-30
11982723